Healthcare Services

Global Axial Spondyloarthritis (axSpA) Market Set for Strong Expansion Reaching $9.83 Billion by 2030 at 8.5% CAGR

March 30, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Axial Spondyloarthritis (axSpA) Market Across 2026–2030?

The market size for axial spondyloarthritis (axspa) has experienced robust growth over recent years. It is anticipated to increase from $6.56 billion in 2025 to $7.09 billion in 2026, expanding at a compound annual growth rate (CAGR) of 8.1%. The expansion observed in the past can be attributed to a heightened awareness of inflammatory spinal disorders, the broadened application of TNF inhibitors, enhanced availability of diagnostic imaging, an increase in specialized rheumatology care, and strengthened efforts toward treatment adherence.

The market for axial spondyloarthritis (axspa) is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of $9.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This projected growth is driven by several factors, including the increasing uptake of JAK inhibitors and IL therapies, growing investments in personalized medicine, the broadening scope of early screening initiatives, wider implementation of digital platforms for disease monitoring, and ongoing advancements in biologic drug development. Key trends anticipated during this forecast period involve the rising embrace of biologic treatments, the increased application of targeted anti-inflammatory medications, an intensified emphasis on early diagnosis and continuous disease monitoring, the development of more personalized treatment strategies, and improved incorporation of digital health technologies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axSpa) market is anticipated to expand due to the growing aging population. An aging population signifies a demographic pattern marked by a greater or increasing percentage of older people in a given population. Managing and treating axSpA among the elderly offers advantages such as enhanced joint function and mobility, better quality of life, prevention of spinal structural damage, lower healthcare expenditures, disability prevention, and refined treatment approaches. For example, Age UK, a UK-registered charity, reported that in 2023, England had 11 million individuals over 65 years old. This figure is forecasted to grow by 10% in the upcoming five years and by 32% by 2043 (equivalent to 1.1 and 3.5 million people, respectively). Furthermore, the 85+ age group, which typically requires the most health and care services, is also expected to experience a rapid increase, rising by 8.2% in the next five years and by 62.7% by 2043 (representing 126,000 and 956,000 people, respectively). Consequently, the expanding aging demographic is fueling the expansion of the axial spondyloarthritis (axSpa) market.

What Segmentation Levels Are Considered In The Axial Spondyloarthritis (axSpA) Market?

The axial spondyloarthritis (axspa) market covered in this report is segmented –

1) By Type: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Subsegments:

1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS

2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Active nr-axSpA, Low-Disease-Activity nr-axSpA

Which Trends Are Impacting The Growth Of The Axial Spondyloarthritis (axSpA) Market?

Companies operating within the axial spondyloarthritis (axSpA) market are dedicated to developing advanced solutions, such as next-generation biologic drug therapies, to satisfy the growing need for effective treatments that tackle inflammation and improve long-term disease management. These biologic therapies work by modulating specific immune pathways, offering a more precise strategy compared to traditional anti-inflammatory drugs, which primarily alleviate symptoms without directly influencing the underlying immune factors. For example, in June 2023, UCB SA, a pharmaceutical company based in Belgium, secured approval from the New European Commission for the marketing authorization of BIMZELX (bimekizumab). This drug is intended for treating adults diagnosed with active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS) who exhibit objective signs of inflammation, indicated by elevated C-reactive protein. These European Union (EU) authorizations signify the drug’s inaugural global marketing licenses for axial spondyloarthritis.

Which Leading Firms Are Contributing To The Growth Of The Axial Spondyloarthritis (axSpA) Market?

Major companies operating in the axial spondyloarthritis (axspa) market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi S.A., Regeneron Pharmaceuticals Inc., Merck & Co. Inc., GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Biogen Inc., Amgen Inc., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Janssen Pharmaceuticals, Acelyrin Inc.

Read the full axial spondyloarthritis (axspa) market report here:

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Which Regions Are Projected To Dominate The Axial Spondyloarthritis (axSpA) Market In The Coming Years?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Axial Spondyloarthritis (axSpA) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12590&type=smp

Browse Through More Reports Similar to the Global Axial Spondyloarthritis (axSpA) Market 2026, By The Business Research Company

Osteoarthritis Global Market Report

https://www.thebusinessresearchcompany.com/report/osteoarthritis-global-market-report

Ankylosing Spondylitis Global Market Report

https://www.thebusinessresearchcompany.com/report/ankylosing-spondylitis-global-market-report

Cervical Spondylosis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795